Many chronic hepatitis B patients and even non-hepatology specialists have a common perception that “small triplets” are good and “large triplets” are bad, and that as long as “large triplets” are converted to “small triplets”, they can rest easy and do not need treatment. If the “small triplets” are converted to “small triplets”, you can rest easy and do not need treatment. This idea is very wrong, if the “small three positive” patients hepatitis B virus DNA is positive, and liver function tests repeatedly fluctuate, it is necessary to carry out treatment, otherwise it is more harmful to the body, more likely to transform into cirrhosis and liver cancer. The “small three positive” is not the same as light, non-infectious Chronic hepatitis B is the first major disease in China, according to the 2010 edition of the “Prevention and Treatment Guidelines for Chronic Hepatitis B”, China’s general population hepatitis B surface antigen carriage rate of 7.18%, according to this projection, China’s existing chronic hepatitis B virus infection of about 93 million people, of which the current patients 20 million cases. Chronic hepatitis B is the most important cause of cirrhosis and primary liver cancer, and about 25% of patients die from the deterioration of liver disease related to hepatitis B virus. The so-called major and minor triplets refer to the e antigen-positive or e antigen-negative immune index of hepatitis B. A positive test is a “major triplet” and a negative test is a “minor triplet”, which only reflects the immune marker status of the body for hepatitis B and does not represent the severity of the disease or the size of the infection. The severity of the disease depends on the indicators of liver function and liver imaging and pathology, while the infectiousness depends on the viral load in the blood. Therefore, many carriers of “major triple-positive” do not need treatment for the time being, but should be reviewed regularly, while patients with “minor triple-positive” should also be analyzed on a case-by-case basis, and should not be generalized to say “no treatment”. The patient with “small triple-positive” should also be analyzed on a case-by-case basis, and it is not possible to generalize “no treatment”. At the same time, “small three positive” does not mean that there is no contagious, but the contagiousness is not as strong as “large three positive”, usually life should still pay attention to the use of items separate from the family, in addition, the family should be timely injection of hepatitis B vaccine. This is a one-sided and flawed understanding of the fact that the virus replication is weakened, the infection is small and the condition is transforming for the better. For ‘small three yang’ patients must be treated differently, the treatment or not depends on the specific situation. ”Theoretically, all patients with “small triplets” should be treated. “The existence of hepatitis B ‘small three positive’ in any form is a potential threat to human health. Our clinical statistics show that 90% of liver cancer patients are ‘small three positive’ patients, and most of the patients with cirrhosis and severe hepatitis B are ‘small three positive’ patients. But from the current actual situation, it is not very realistic to treat all of them, and this can be treated differently according to the situation.” If a “small three positive” patient is positive for hepatitis B virus DNA, liver function tests repeatedly fluctuate, often clinically known as HBeAg negative slow hepatitis B, mainly due to hepatitis B virus mutation, at this time must be antiviral treatment. Many doctors may not think that treatment is needed for patients with “small triple-positive” hepatitis B virus with positive DNA and normal liver function, but clinically, liver puncture reveals that the degree of inflammation and fibrosis of liver histology in these patients is usually more serious than in “large triple-positive” patients, and some patients have even developed early stage Some of these patients have already developed early cirrhosis. Therefore, these patients should be considered for antiviral therapy as early as possible. patients over 40 years old with 10 years of disease duration who are HBV DNA positive, most of whom have different degrees of inflammation and liver fibrosis, should be treated with active and effective antiviral therapy to prevent the occurrence of cirrhosis and hepatocellular carcinoma, improve the patient’s It is very important to prevent the occurrence of cirrhosis and hepatocellular carcinoma, improve patients’ prognosis and enhance their survival quality. Generally speaking, patients with the following three conditions must be treated in a timely manner: 1) having obvious symptoms, such as fatigue, loss of appetite, abdominal distension, and discomfort in the liver area, etc. 2) having repeated fluctuations in liver function, and having a change in liver function. 2. Repeated fluctuations in liver function, elevated transaminases and serum bilirubin, and reduced albumin. 3.Hepatitis B virus deoxyribonucleic acid (HBVDNA) test is positive. The first thing you need to do is to take a look at the actual product. The advantage of oral medication is that it is simple and convenient to take, with few side effects, and many people are easily accepted. The drug itself has a strong inhibitory effect, and long-term use can bring down the amount of virus in the body to a very low level, but the disadvantage is that it is particularly easy to relapse after stopping the drug, and the relapse rate is as high as 60% to 80% a year after stopping the drug. Therefore, oral medication may require long-term medication, or even lifelong medication, but long-term medication can create the risk of drug resistance, and once resistance occurs, it can lead to viral rebound and hepatitis recurrence, increasing the cost of treatment. Another class of drugs is interferon, the advantage is that it can be achieved through a limited course of treatment (the standard course of treatment is 48 weeks) to stop the drug, and the relapse rate is low, the two-year relapse rate is less than 20%, but the disadvantage is that the side effects are large, part of the people can not tolerate, such as in the loss of liver cirrhosis or have cirrhosis ascites; older, more than 65 years old; or have heart disease, diabetes, kidney disease, etc. in the body, it is not suitable for use . In addition, economic factors are also an important reason for some patients to give up interferon treatment. In contrast, in the clinical hepatitis B virus infection in the immune clearance period (transaminase level is high), young, primary treatment, low viral load of chronic hepatitis B patients are more suitable for interferon therapy, “because the immune function of this part of the population is relatively strong, with interferon treatment can further improve immunity, the effect will be more durable, some patients can even achieve hepatitis B surface antigen The result is close to clinical cure.” Young patients can try it if they have a short-term need to go on to higher education or get married and have children.